PCN157 Model-Based Cost–Utility Analysis of Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Treatment Induced Anaemia in the UK NHS  by Snowsill, T. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A641
and capecitabine monotherapy in terms of incidence of diarrhea, vomiting, sto-
matitis/mucositis. The hand-foot syndrome occurrred in less than 5% in case of 
tegafur. Tegafur (in monotherapy or in combination with calcium folinate) is less 
costly than capecitabine. The difference in costs in favor of tegafur monotherapy 
amounted to € 1,956.97 per 1 patient per 6 months or € 3,778.53 per year; of tegafur + 
calcium folinate - € 2,168.12 and € 4,220.06 per 1 patient per 6 and 12 months, respec-
tively. ConClusions: Tegafur is a cost-saving option compared with capecitabine 
with similar efficacy and safety.
PCN155
Cost-EffECtivENEss ANAlysis of BENdAmustiN-RituximAB ComPAREd 
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objeCtives: There is new RCT phase 3 clinical evidence that bendamustin-
rituximab (B-R) is more effective in terms of progression free survival compared 
to the standard of care CHOP-rituximab (CHOP-R) in indolent non-Hodgkin lym-
phoma (iNHL). Based on this RCT, we performed a cost-utility analysis of B-R com-
pared to CHOP-R in the treatment of follicular iNHL (stage III and IV) in the Czech 
Republic. Methods: We developed a life-time Markov cohort model with 28-day 
cycle length and 5 health states, i.e. on treatment, rituximab maintenance (R-M), 
stable disease, progression and death. Additionally, we modeled adverse effects 
of treatment and four sub-states during progression (observation, imunochemo-
therapy, R-M, post R-M). Transition probabilities and utilities were derived from 
published literature. Resource use (costs) was calculated from health care payer’s 
perspective in cooperation with major Czech hemato-oncologic experts. Costs and 
outcomes were discounted by 3.5%. Probabilistic sensitivity analysis (PSA) with 
1000 iterations using a willingness to pay (WTP) threshold equal to 3 times GDP per 
capita (40 100 EUR) in the Czech Republic was performed. Results: Over a life-time 
horizon, B-R compared to CHOP-R brings additional 1.21 QALY (7.47 vs. 6.26) and 1.31 
LYG (9.74 vs. 8.43). The incremental total costs were 1,368 EUR (total life time costs 
for B-R and CHOP-R were 43,080 EUR and 41,712 EUR, respectively). ICERs thus equal 
to 1,133 EUR/QALY and 1,044 EUR/LYG. The results of the PSA show that B-R is cost-
effective in 100% iterations under the WTP threshold; and simultaneously in 99.3% 
iterations is cost-effective while using threshold equal to 7,300 EUR. ConClusions: 
B-R proved that it is a highly cost-effective therapy in patients with follicular iNHL. 
The higher costs of initial bendamustin treatment are in the long-term horizon 
offset by substantial savings of progression costs. There is 100% probability of B-R 
being cost-effective at the selected WTP threshold.
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objeCtives: The inhibition of epidermal growth factor receptor (EGFR) signaling 
pathway by innovative therapeutics presents promising upshots in oncology. Our 
study aims to quantify first-line treatment with afatinib, an irreversible tyrosine 
kinase inhibitor, compared to pemetrexed+cisplatin (pem+cis), for patients with met-
astatic lung adenocarcinoma harboring common EGFR mutations (DEL19 or L858R) in 
the Netherlands. Methods: An area under the curve partitioned survival model, con-
structed to quantify lifetime consequences of therapy with afatinib versus pem+cis, 
was amended to the Netherlands. The updated (2014) LUX-Lung 3 trial results and 
data from public sources were used to populate the model. Study outcomes were 
expressed in quality-adjusted life years (QALY), incremental cost-utility ratios (ICUR) 
and net monetary benefits (NMB). The analyses were conducted from health care and 
societal perspectives. Uncertainty assessment was performed using one-way and 
probabilistic sensitivity analyses (PSA). Results: Metastatic lung adenocarcinoma 
patients with common EGFR mutations (89%) had higher overall survival when treated 
with afatinib compared to pem+cis (HR: 0.78, p= 0.10). The corresponding base-case 
ICUR was < € 20,000/QALY gained. For the subgroup of patients harboring DEL19 muta-
tions (49%), treatment with afatinib resulted in cost-savings. Although NMB calcula-
tions were favorable for the genotype-directed therapy, inclusion of the entire patient 
population (all EGFR mutations) resulted in higher incremental costs. PSA results of 
lung adenocarcinoma patients with common EGFR mutations showed that afatinib 
is > 95% cost-effective compared to pem+cis at a € 80,000 threshold. ConClusions: 
This study shows that genotype-directed therapy with afatinib improved survival in 
metastatic lung adenocarcinoma and translated itself as value-for-money, particu-
larly for the DEL19 subgroup, in the Netherlands. Further research is encouraged to 
compare afatinib with reversible EGFR inhibitors in this setting.
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objeCtives: To assess the cost–utility of erythropoiesis-stimulating agents (ESAs) 
in conjunction with red blood cell transfusions (RBCTs) in patients with cancer-
treatment induced anaemia (CIA). Methods: A cost–utility analysis from an NHS 
and personal social services perspective was conducted by developing an ad hoc 
economic model. A lifetime time horizon was used and outcomes were discounted 
at 3.5% per annum. All ESAs were assumed to have the same clinical effective-
ness. Haemoglobin (Hb) levels were assumed to drive health-related quality of life 
(HRQoL), with haemoglobin linearly mapped to utility. This was used to calculate 
lower than that with Herceptin-IV in the management of patients with HER2+ EBC 
and MBC. Hence, the substitution of Herceptin-IV with Herceptin-SC can produce 
valuable savings for the Greek health care system, especially in the current eco-
nomic environment where hospitals’ pharmaceutical budget has significantly been 
reduced.
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objeCtives: Due to increasing costs in cancer management, there is a crescent 
need to rationally allocate resources in health care systems. Recently, a head-to-
head phase III study (CALGB80405) showed no significant difference in OS and PFS 
for first line (1L) mCRC in KRAS wild-type (wt) patients amongst bevacizumab (Bev) 
and cetuximab (Cet) – the most commonly used biologics in this setting. Since 
benefit of both drugs is comparable, the aim of the study was comparing treatment 
costs of Bev vs. Cet in 1L KRAS wt mCRC. Methods: A cost-minimization analysis 
was conducted under payer perspective in Brazilian Supplementary Healthcare 
System. Backbone chemotherapy regimens (mFOLFOX6 and FOLFIRI) were based 
on CALGB80405 trial. Direct medical costs regarding drug acquisition, material and 
procedures/service fees were included. Adverse events management costs were 
excluded. The resource usage data was taken from the literature and drug labels. 
Costs were taken from CMED price list and UNIMED reimbursement lists. A uni-
variate sensitivity analysis was conducted varying parameters from ±20% range. 
Results were reported in Brazilian Reais (BRL). Results: The average monthly 
cost per patient was lower with Bev: BRL23’945 (Bev+mFOLFOX6) vs. BRL30’017 
(Cet+mFOLFOX6) – reduction of 20.2% - and BRL23’008 (Bev+FOLFIRI) vs. BRL29’075 
(Cet+FOLFIRI) – reduction of 20.9%. Average monthly cost per patient according to 
mFOLFOX6/FOLFIRI usage proportion reported on CALGB80405 was BRL23’699 (Bev) 
and BRL29’766 (Cet); considering PFS data presented in the trial, the average total 
treatment cost was estimated as BRL256’899 (Bev) and BRL311’060 (Cet). The sensi-
tivity analysis showed that model was more influenced by Cet price, Bev price and 
patient height. ConClusions: Bev is a cost-saving choice for 1L KRAS wt mCRC 
in combination with chemotherapy, potentially achieving around 20% of reduction 
in monthly direct treatment costs compared to Cet, mainly because of Cet higher 
total acquisition costs and weekly administration schedule, resulting in additional 
resource consumption.
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objeCtives: To analyze the economic impact of the incorporation of trastu-
zumab subcutaneous (TSC) in a University Hospital according to real data of our 
patients. Methods: Retrospective cost minimization study that included patients 
diagnosed with breast cancer treated with trastuzumab intravenous (TIV) from 
april 2013 to april 2014. The demographic data of the patients (age and weight) 
and antineoplastic treatments used were obtained from the computer program 
Hospiwin®. An economic model was developed in Excel® data base, based on the 
dose used in previous clinical trials: IV loading dose of 8mg/kg and after 6mg/kg/3 
weeks and SC fixed dose of 600 mg/3 weeks. The time horizon was one year and 
the perspective of medical leadership of the hospital was used. The Spain cost of 
TSC is not aproved yet. Two posibilities was analyzed: The cost of filing 600mg of 
TSC equal to the cost of a 68kg patient with TIV (situation A) and the cost of a 63kg 
patient with TIV (situation B). A sensitivity analisys included the cost of using an 
oncology chair (168€ /treatment) was performed. Results: During the study period 
371 patients were treated for breast cancer. Of these 75 were treated with TIV (20.2%), 
with an average weight of 71.5 kg (SD= 17.1) and a cost of 990,996.88€ /per year. If 
all patients had been treated with TSC: Situation A the total spending would be 
829,965.4€ ; situation B the total spending would be 768,938.5€ . So the savings would 
be 161,031.4€ (19.4%) and 222,058.3€ (28.8%) respectively. If the cost of oncology 
chair (not necessary for the TSC) it´s included, the savings would be 253,549.4€ and 
314,576.3 respectively. ConClusions: In this study we wanted to show how TSC 
saved costs in all of the situations analyzed. The TSC is a therapeutic innovation 
that helps promote the systems health´s sustainability.
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objeCtives: To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs 
capecitabine, for advanced colorectal cancer (CRC) in adult patients. Methods: 
Indirect comparison and network meta-analysis of clinical efficacy and safety of 
tegafur vs capecitabine and tegafur + calcium folinate vs capecitabine were per-
formed. Cost-minimization analysis (CMA) with calculation of cost minimization 
difference was used for economic evaluation of studied drugs. Results: There 
was no statistically significant difference in the full and partial objective tumor 
response between oral tegafur (both in monotherapy or in combination with calcium 
folinate) and capecitabine for advanced CRC treatment in an indirect comparison 
and network meta-analysis. Capecitabine vs tegafur + calcium folinate has less 
3-4th grade stomatitis but there was no difference in the incidence of diarrhea and 
3-4th grade nausea/vomiting. There was no difference in safety between tegafur 
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(comparison cohort) who were the same age, race, and gender were identified and 
matched. A random index date was chosen to minimize selection bias. Patients in 
both cohorts were required to be at least age 18 years, with continuous medical and 
pharmacy benefits 1-year pre- and 1-year post-index date. One-to-one propensity 
score matching (PSM) was used to compare health care costs and utilizations during 
the follow-up period, between the diseased and comparison cohorts, and adjusted 
for baseline demographic and clinical characteristics. Results: After risk adjust-
ment by PSM, a total of 19,079 patients in each cohort were matched. Significantly 
more breast cancer patients had inpatient admissions (23.77% vs. 12.56%, p< 0.0001) 
and long-term care (7.77% vs. 6.60%, p< 0.0001), other service (99.88% vs. 87.86%, 
p< 0.0001) and pharmacy visits (77.80% vs. 68.85%, p< 0.0001), compared to those 
without breast cancer. Breast cancer patients also incurred significantly higher 
inpatient ($2,141 vs. $1,537, p< 0.0001), long-term care ($7,471 vs. $5,335, p< 0.0001), 
other service visit ($23,592 vs. $14,780, p< 0.0001) and pharmacy costs ($3,379 vs. 
$2,787, p< 0.0001) compared to those in the comparison cohort. ConClusions: 
Breast cancer patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs compared to those without the disease.
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objeCtives: Paclitaxel and docetaxel are used for the treatment of MBC in China. 
However, one important drawback, particularly with docetaxel, is the potential for 
dose-limiting toxicity. To improve the side effect profile and efficacy of paclitaxel, 
an albumin-bound formulation (nab-paclitaxel) is currently available in China 
(Abraxane®). Clinical trials have demonstrated that nab-paclitaxel is safer and more 
effective than both docetaxel and paclitaxel. To provide economic data for China, 
a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives 
to paclitaxel was conducted. Methods: Clinical data was obtained from a meta 
analysis of randomized trials comparing either nab-paclitaxel (260 mg/m2 q3wk) 
or branded docetaxel (100 mg/m2 q3wk) to solvent-based branded paclitaxel (175 
mg/m2 q3wk). Health care resource use for the delivery of chemotherapy and the 
management of grade 3/4 toxicity was collected from a time and motion study 
in three Chinese cancer centers and from a survey of clinicians. Using the Time 
Trade-off technique, treatment preferences and utility estimates were obtained 
from interviewing 28 cancer patients from two centres in China. All costs were 
reported in 2014 $U. S. Results: Nab-paclitaxel had the most favourable safety 
profile characterized with the lowest incidence of grade 3/4 neutropenia, febrile 
neutropenia, anemia and stomatitis. This translated into lower costs for managing 
the grade 3/4 side effects of nab-paclitaxel relative to both docetaxel and paclitaxel 
($21 vs. $166 vs. $81). In the preference assessment, 22 of 28 (78.6%) patients selected 
nab-paclitaxel as their preferred agent. As an alternative to paclitaxel, the cost per 
quality adjusted life year (QALY) gained was more favourable with nab-paclitaxel 
than docetaxel ($57,900 vs. $130,600 respectively). ConClusions: Nab-paclitaxel is 
an economically attractive alternative to paclitaxel and docetaxel in MBC, providing 
a substantially lower cost per QALY. Additionally in the patient preference survey, 
78.6% of patients selected nab-paclitaxel as their preferred agent.
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objeCtives: Targeted therapy with ALK inhibitor crizotinib offers significant 
improvement in clinical outcome for treatment of EML4–ALK fusion positive non-
small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of 
companion EML4-ALK genetic testing in combination with crizotinib treatment in 
the second-line setting for advanced NSCLC in Ontario. Methods: We performed 
a cost-effectiveness analysis using a Markov model from a Ministry of Health per-
spective and a lifetime horizon. Transition probabilities and mortality rates were 
calculated based on the data of a recent second-line randomized trial of crizotinib 
versus chemotherapy (Shaw et al. New Engl J Med 2013). Costs were obtained from 
OCCI database, public labs and Princess Margaret Hospital. All parameters were 
varied separately in one-way and selected two-way sensitivity analyses. Various 
scenarios to assess the impact of model assumptions about testing and treatment 
were conducted. Results:  The use of pemetrexed and docetaxel in ALK-rearranged 
NSCLC, based on our preliminary model, could yield as much as 0.539 QALY and 
0.429 QALY respectively, assuming no crossover from chemotherapy to crizotinib. 
Average costs per patient based on the preliminary model are estimated at CAD 
$19,388 for pemetrexed and $$33,226for docetaxel, with incremental cost-effective-
ness ratios of $333,595/QALY and $125,812/QALY gained respectively. The results of 
the one-way sensitivity analysis indicated that the primary drivers of the ICER were 
the utilities and cost of crizotinib treatment. The model was least sensitive to IHC 
and FISH genetic test costs, re-biopsy cost, probability of progression while on pem-
etrexed treatment and probability of re-biopsy. ConClusions: EML4–ALK genetic 
testing in combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug costs 
would be required to make this strategy economically feasible.
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incremental quality-adjusted life years (QALYs) while ESAs were administered 
and during a Hb “normalisation period” following cancer treatment. Incremental 
long-term QALYs were accrued solely through extrapolated overall survival. Short-
term mortality and HRQoL associated with adverse events and RBCTs were not 
modelled. Costs included: ESA acquisition (list prices, British National Formulary) 
and administration, RBCT, additional blood tests with ESA therapy, and adverse 
event costs. Results: All ESAs except epoetin beta and darbepoetin alfa were 
cost-effective versus using RBCT only at an upper cost-effectiveness threshold of 
£30,000/QALY. Incremental cost-effectiveness ratios (ICERs) ranged from £19,400/
QALY (biosimilar epoetin alfa) to £35,000/QALY (epoetin beta). Probabilistic sensi-
tivity analysis showed that biosimilar epoetin alfa was cost-effective at the lower 
cost-effectiveness threshold of £20,000/QALY in 50.9% of simulations. In 19.5% of 
simulations it was clinically effective but not cost-effective and in 31.4% of simula-
tions it was dominated by RBCT only. Additional sensitivity analyses demonstrated 
that overall survival was one of the most influential and uncertain parameters. 
When the survival advantage of ESAs (not statistically significant) was removed, the 
ICERs for all ESAs were over £100,000/QALY. ConClusions:  There is substantial 
uncertainty regarding the impact of ESA therapy on overall survival, which leads to 
significant uncertainty about the cost-effectiveness of ESAs in CIA.
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objeCtives: To demonstrate the impact of QALY weightings based on the burden-of-
illness (BoI) of pancreatic cancer on the incremental cost-effectiveness ratio (ICER) of 
nab-paclitaxel plus gemcitabine (NPG) versus gemcitabine (G). Methods: A markov 
model using data from the MPACT trial plus resource use data and costs from NHS 
Scotland have been submitted to the Scottish Medicines Consortium. The base case 
ICER was £52,885/QALY based on a cost of £8,232 and a QALY gain of 0.156 (SMC DAD). 
QALY weightings up to a maximum of 2.5 distributed across six modifier factors, 
including BoI, have been proposed (NICE consultation on Value Based Assessment), 
with BoI measured according to proportional QALY shortfall associated with the con-
dition. The estimated 98% loss of healthy life (proportional QALY shortfall) in pan-
creatic cancer (Hutchings 2014) represents an almost complete loss of life, and thus 
a very high BoI. A BoI weighting of 2.5 (maximum weighting allocated entirely to BoI, 
or BoI FULL) and an alternative BoI weighting of 1.417 (maximum weighting shared 
equally between six modifiers, so 1/6thof 2.5, or BoI PARTIAL) were therefore applied to 
the QALY gain of NPG versus G. Results:  The BoI FULL weighting gives an adjusted 
QALY gain for NPG versus G of 0.39 and a corresponding ICER of £21,108/QALY. The 
BoI PARTIAL weighting gives an adjusted QALY gain for NPG versus G of 0.221 and 
a corresponding ICER of £37,249/QALY. ConClusions: Various ways of accounting 
for disease severity can be considered and made workable by HTAs, including QALY 
weightings according to proportional QALY shortfall. The adjusted QALY gain and 
corresponding ICERs of NPG versus G in pancreatic cancer show that the value of 
medicines for life-threatening ‘end-of-life’ conditions with a high relative shortfall 
can be reflected by an appropriate system of QALY weightings.
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objeCtives: The objective of the current analysis was to assess the cost-effective-
ness of lapatinib plus capecitabine versus capecitabine alone in human epidermal 
growth factor receptor-2-positive metastatic breast cancer patients from the third 
party payer perspective over a time horizon of ten years. Methods: A half cycle 
corrected Markov chain model comprising 3 health states (stable, progression and 
death) was developed to estimate the projected clinical and economic implications 
of Lapatinib. Transition probabilities were estimated based on the results from the 
EGF100151 clinical trial of Lapatinib. Health state utilities and major adverse events 
were obtained from published sources. Direct medical costs were obtained from the 
third party payer list. Costs (in 2013 EGP) and effects were discounted at 3.5% annu-
ally. One way sensitivity analyses were conducted. Results:  The economic evalu-
ation of lapatinib plus capecitabine as combination therapy resulted in additional 
cost of 1,597,796 EGP, with an incremental positive effect of 5.7 quality adjusted life 
years (QALY) or an incremental cost-effectiveness ratio (ICER) of 277,169 EGP/QALY 
gained. The overall survival of the two arms was found to have the greatest impact 
on the results. ConClusions: Compared with our willingness-to-pay threshold 
stated by world health organization for middle and lower income countries, the 
addition of lapatinib to capecitabine is not clearly cost-effective; and most likely to 
result in an ICER higher than the threshold limit.
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objeCtives: To evaluate health care resource utilization and costs among patients 
diagnosed with breast cancer in the Medicaid program. Methods: Patients diag-
nosed with breast cancer (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 174, 233.0, 238.3, 239.3) were identi-
fied using Medicaid data from January 1, 2008 through December 31, 2010. The initial 
diagnosis date was designated as the index date. Patients without breast cancer 
